Review Article| Volume 50, ISSUE 2, P113-123, February 2018

Download started.


Interferon-free direct-acting antiviral therapy for acute hepatitis C virus infection in HIV-infected individuals: A literature review

Published:November 27, 2017DOI:


      Dramatic rises in hepatitis C virus (HCV) coinfection rates in human immunodeficiency virus (HIV)-infected individuals have been observed recently, largely attributable to increasing recreational drug use combined with increased testing for HCV. In the era of direct-acting antiviral (DAA) therapy, treatment of acute HCV infection in HIV-infected individuals with short durations of these drugs may potentially reduce the disease and economic burden associated with HCV infection as well as reducing the likelihood of onward HCV transmission. We performed an extensive literature search of PubMed, Embase and Google Scholar up to 05 September 2017 for clinical trials of acute HCV infection in HIV-infected individuals. In the studies identified, rates of sustained virologic response at 12 weeks post-treatment (SVR12) ranged from 21% with 6 weeks of therapy up to 92% with 12 weeks of therapy with sofosbuvir and ribavirin. Ledipasvir/sofosbuvir for 6 weeks achieved an SVR of 77%. No HIV-related events occurred regardless of whether patients were receiving antiretroviral therapy (ART) and DAAs were well tolerated. Data is currently limited with regards to optimal regimens and durations of therapy, which need to be tailored based on potential interactions with concurrent ART and consideration for the fact that patients with higher baseline HCV RNA levels may require an extended duration of treatment.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Birger R.B.
        • Le T.
        • Kouyos R.D.
        • Grenfell B.
        • Hallett T.B.
        • Khudyakov Y.E.
        The impact of HCV therapy in a high HIV–HCV prevalence population: a modeling study on people who inject drugs in Ho Chi Minh City, Vietnam.
        PLoS One. 2017; 12: e0177195
        • Taylor L.E.
        • Swan T.
        • Mayer K.H.
        HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms.
        Clin Infect Dis. 2012; 55
        • Quan V.M.
        • Go V.F.
        • Nam Van L.
        • et al.
        Risks for HIV, HBV, and HCV infections among male injection drug users in northern Vietnam: a case-control study.
        AIDS Care. 2009; 21: 7-16
        • Garten R.J.
        • Lai S.
        • Zhang J.
        • et al.
        Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China.
        Int J Epidemiol. 2004; 33: 182-188
        • Danta M.
        • Brown D.
        • Bhagani S.
        • Pybus O.G.
        • Sabin C.A.
        • Nelson M.
        • et al.
        Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours.
        AIDS. 2007; 21: 983-991
        • Hoornenborg E.
        • Achterbergh R.C.A.
        • Schim van der Loeff M.F.
        • et al.
        MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection.
        AIDS. 2017; 31: 1603-1610
        • Elliot E.R.
        • Singh S.
        • Tyebally S.
        • Gedela K.
        • Nelson M.
        Recreational drug use and chemsex among HIV-infected in-patients: a unique screening opportunity.
        HIV Med. 2017; 18: 525-531
        • Tohme R.A.
        • Holmberg S.D.
        Transmission of hepatitis C virus infection through tattooing and piercing: a critical review.
        Clin Infect Dis. 2012; 54: 1167-1178
        • Amodio E.
        • Di Benedetto M.A.
        • Gennaro L.
        • Maida C.M.
        • Romano N.
        Knowledge, attitudes and risk of HIV, HBV and HCV infections in hairdressers of Palermo city (South Italy).
        Eur J Public Health. 2010; 20: 433-437
        • Shores N.J.
        • Maida I.
        • Soriano V.
        • Núnez M.
        Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients.
        J Hepatol. 2008; 49: 323-328
        • Thomson E.C.
        • Fleming V.M.
        • Main J.
        • et al.
        Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men.
        Gut. 2011; 60: 837-845
        • Panel I.C.
        Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference.
        AIDS. 2011; 25: 399-409
        • Glässner A.
        • Eisenhardt M.
        • Kokordelis P.
        • et al.
        Impaired CD4+ T cell stimulation of NK cell anti-fibrotic activity may contribute to accelerated liver fibrosis progression in HIV/HCV patients.
        J Hepatol. 2013; 59: 427-433
        • Soriano V.
        • Vispo E.
        • Fernandez-Montero J.V.
        • Labarga P.
        • Barreiro P.
        Update on HIV/HCV coinfection.
        Curr HIV/AIDS Rep. 2013; 10: 226-234
        • Joshi D.
        • O’Grady J.
        • Dieterich D.
        • Gazzard B.
        • Agarwal K.
        Increasing burden of liver disease in patients with HIV infection.
        Lancet. 2011; 377: 1198-1209
        • Miller M.F.
        • Haley C.
        • Koziel M.J.
        • Rowley C.F.
        Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis.
        Clin Infect Dis. 2005; 41: 713-720
        • Chung R.T.
        • Andersen J.
        • Volberding P.
        • et al.
        Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
        N Engl J Med. 2004; 351: 451-459
        • Dore G.J.
        • Hellard M.
        • Matthews G.V.
        • et al.
        Effective treatment of injecting drug users with recently acquired hepatitis C virus infection.
        Gastroenterology. 2010; 138
        • Taylor L.E.
        • DeLong A.K.
        • Maynard M.A.
        • et al.
        Acute hepatitis C virus in an HIV clinic: a screening strategy, risk factors, and perception of risk.
        AIDS Patient Care STDS. 2011; 25: 571-577
        • D’Ambrosio R.
        • Degasperi E.
        • Colombo M.
        • Aghemo A.
        Direct-acting antivirals: the endgame for hepatitis C?.
        Curr Opin Virol. 2017; 24: 31-37
      1. EASL recommendations on treatment of hepatitis C.
        J Hepatol. 2017; 66: 153-194
        • Montes M.L.
        • Olveira A.
        • Ahumada A.
        • et al.
        Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection.
        AIDS. 2017; 31: 1253-1260
        • Chung R.T.
        • Davis G.L.
        • Jensen D.M.
        • et al.
        Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.
        Hepatology. 2015; 62: 932-954
        • Diepolder H.M.
        Interferon-a for hepatitis C: antiviral or immunotherapy?.
        J Hepatol. 2004; 40: 1030-1031
        • Ulsenheimer A.
        • Gerlach J.T.
        • Gruener N.H.
        • et al.
        Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C.
        Hepatology. 2003; 37: 1189-1198
        • Holz L.
        • Rehermann B.
        T cell responses in hepatitis C virus infection: historical overview and goals for future research.
        Antiviral Res. 2015; 114: 96-105
        • Duong F.H.T.
        • Filipowicz M.
        • Tripodi M.
        • La Monica N.
        • Heim M.H.
        Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A.
        Gastroenterology. 2004; 126: 263-277
        • Gale Michael J.J.
        • Korth M.J.
        • Tang N.M.
        • et al.
        Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein.
        Virology. 1997; 230: 217-227
        • Boesecke C.
        • Ingiliz P.
        • Reiberger T.
        • et al.
        Dual treatment of acute HCV infection in HIV co-infection: influence of HCV genotype upon treatment outcome.
        Infection. 2016; 44: 93-101
        • Matthews G.V.
        • Hellard M.
        • Haber P.
        • et al.
        Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C.
        Clin Infect Dis. 2009; 48: 650-658\r10.1086/596770
        • Hullegie S.J.
        • Claassen M.A.A.
        • Van Den Berk G.E.L.
        • et al.
        Boceprevir, peginterferon and ribavirin for acute hepatitis C in HIV infected patients.
        J Hepatol. 2016; 64: 807-812
        • Boesecke C.
        • Jagjit Singh G.K.
        • Scholten S.H.-A.
        • et al.
        Telaprevir-containing triple therapy in acute HCV coinfection: the CHAT study.
        Antivir Ther. 2017; ([Epub ahead of print])
        • Okoye A.A.
        • Picker L.J.
        CD4+ T-cell depletion in HIV infection: mechanisms of immunological failure.
        Immunol Rev. 2013; 254: 54-64
        • Mussini C.
        • Lorenzini P.
        • Cozzi-Lepri A.
        • et al.
        CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study.
        Lancet HIV. 2015; 2: 98-106
        • Thornhill J.
        • Inshaw J.
        • Kaleebu P.
        • et al.
        Brief report: enhanced normalization of CD4/CD8 ratio with earlier antiretroviral therapy at primary HIV infection.
        J Acquir Immune Defic Syndr. 2016; 73: 69-73
        • Basso M.
        • Parisi S.G.
        • Mengoli C.
        • et al.
        Sustained virological response and baseline predictors in HIV–HCV coinfected patients retreated with pegylated interferon and ribavirin after failing a previous interferon-based therapy: systematic review and meta-analysis.
        HIV Clin Trials. 2013; 14: 127-139
        • Churchill D.
        • Waters L.
        • Ahmed N.
        • et al.
        British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015.
        HIV Med. 2016; 17: s2-s104
        • Naggie S.
        • Marks K.M.
        • Hughes M.
        • et al.
        Sofosbuvir plus ribavirin without interferon for treatment of acute hepatitis c virus infection in HIV-1-Infected individuals: SWIFT-C.
        Clin Infect Dis. 2017; 64: 1035-1042
        • Martinello M.
        • Gane E.
        • Hellard M.
        • et al.
        Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: the DARE-C II study.
        Hepatology. 2016; 64: 1911-1921
        • El Sayed A.
        • Barbati Z.R.
        • Turner S.S.
        • et al.
        Sofosbuvir in the treatment of early HCV infection in HIV-infected men.
        HIV Clin Trials. 2017; 18: 60-66
        • Rockstroh J.K.
        • Bhagani S.
        • Hyland R.H.
        • et al.
        Ledipasvir–sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial.
        Lancet Gastroenterol Hepatol. 2017; 2: 347-353
        • Feld J.J.
        • Hoofnagle J.H.
        Mechanism of action of interferon and ribavirin in treatment of hepatitis C.
        Nature. 2005; 436: 967-972
        • Feld J.J.
        • Jacobson I.M.
        • Sulkowski M.S.
        • Poordad F.
        • Tatsch F.
        • Pawlotsky J.M.
        Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection.
        Liver Int. 2017; 37: 5-18
        • Clark V.
        • Nelson D.R.
        The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C.
        Liver Int. 2012; 32: 103-107
        • Hézode C.
        • Bronowicki J.P.
        Ideal oral combinations to eradicate HCV: the role of ribavirin.
        J Hepatol. 2016; 64: 215-225
        • Webster D.P.
        • Klenerman P.
        • Dusheiko G.M.
        Lancet seminar — hepatitis C.
        Lancet (London England). 2015; 385: 1124-1135
        • Piroth L.
        • Wittkop L.
        • Lacombe K.
        • et al.
        Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients — French ANRS CO13 HEPAVIH cohort.
        J Hepatol. 2017; 67: 23-31
        • Bruno G.
        • Saracino A.
        • Scudeller L.
        • et al.
        HCV-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?.
        Int J Infect Dis. 2017; 62: 64-67
        • Rodriguez-Torres M.
        • Gaggar A.
        • Shen G.
        • et al.
        Sofosbuvir for chronic hepatitis C virus infection genotype 1–4 in patients coinfected with HIV.
        J Acquir Immune Defic Syndr. 2015; 68: 543-549
      2. Liverpool HIV interactions.
        2017 ( [Accessed 14 June 2017])
        • Saeed S.
        • Strumpf E.C.
        • Walmsley S.L.
        • et al.
        How generalizable are the results from trials of direct antiviral agents to people coinfected with HIV/HCV in the real world?.
        Clin Infect Dis. 2016; 62: 919-926
        • Deterding K.
        • Grüner N.
        • Buggisch P.
        • et al.
        Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial.
        Lancet Infect Dis. 2013; 13: 497-506
        • Boesecke C.
        • Vogel M.
        HIV and hepatitis C co-infection: acute HCV therapy.
        Curr Opin HIV AIDS. 2011; 6: 459-464
        • Boesecke C.
        • van Assen S.
        • Stellbrink H.J.
        • et al.
        Peginterferon-alfa mono-therapy in the treatment of acute hepatitis C in HIV-infection.
        J Viral Hepat. 2014; 21: 780-785
        • Langhans B.
        • Nischalke H.D.
        • Kr??mer B.
        • et al.
        Increased peripheral CD4+ regulatory T cells persist after successful direct-acting antiviral treatment of chronic hepatitis C.
        J Hepatol. 2017; 66: 888-896
        • Tumino N.
        • Casetti R.
        • Fabbri G.
        • et al.
        In HIV/HCV co-infected patients T regulatory and myeloid-derived suppressor cells persist after successful treatment with directly acting antivirals.
        J Hepatol. 2017; 67: 422-424
        • Abdel-Hakeem M.S.
        • Bédard N.
        • Badr G.
        • et al.
        Comparison of immune restoration in early versus late alpha interferon therapy against hepatitis C virus.
        J Virol. 2010; 84: 10429-10435
        • Steininger K.
        • Boyd A.
        • Dupke S.
        • et al.
        HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
        J Viral Hepat. 2017; 24: 832-839
        • Miller W.C.
        • Rosenberg N.E.
        • Rutstein S.E.
        • Powers K a.
        Role of acute and early HIV infection in the sexual transmission of HIV.
        Curr Opin HIV AIDS. 2010; 5: 277-282
        • Brenner B.G.
        • Roger M.
        • Routy J.
        • et al.
        High rates of forward transmission events after acute/early HIV-1 infection.
        J Infect Dis. 2007; 195: 951-959
        • Martin N.K.
        • Thornton A.
        • Hickman M.
        • et al.
        Can hepatitis C virus (HCV) direct-Acting antiviral treatment as prevention reverse the HCV epidemic among men who have sex with men in the United Kingdom? Epidemiological and modeling insights.
        Clin Infect Dis. 2016; 62: 1072-1080
        • Boerekamps A.
        • van den Berk G.
        • Lauw F.
        • Leyten E.M.S.
        • Arends J.E.
        Substantial decline in acute hcv infections among dutch HIV + MSM after daa roll out.
        CROI 2017. 2017;
        • Wiegand J.
        • Buggisch P.
        • Boecher W.
        • et al.
        Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study.
        Hepatology. 2006; 43: 250-256
        • Fierer D.S.
        • Dieterich D.T.
        • Mullen M.P.
        • et al.
        Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men.
        Clin Infect Dis. 2014; 58: 873-879
        • Shah S.
        • Chowdhury A.
        • Mehta R.
        • et al.
        Sofosbuvir plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India.
        J Viral Hepat. 2017; 24: 371-379
        • Gilleece Y.C.
        • Browne R.E.
        • Asboe D.
        • et al.
        Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin.
        J Acquir Immune Defic Syndr. 2005; 40: 41-46
        • Deterding K.
        • Spinner C.D.
        • Schott E.
        • et al.
        Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study.
        Lancet Infect Dis. 2017; 17: 215-222
        • Basu P.P.
        • Shah N.J.
        • Aloysius M.M.
        • Brown Jr., R.S.
        Sofosbuvir and ledipasvir versus sofosbuvir and simeprevir for acute hepatitis C: A RCT: SLAM C study.
        Hepatol Int. 2016; 10: S14-S15
        • Naggie S.
        • Cooper C.
        • Saag M.
        • et al.
        Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1.
        N Engl J Med. 2015; 373: 705-713
        • Tillmann H.L.
        • Thompson A.J.
        • Patel K.
        • et al.
        A polymorphism near IL28 B is associated with spontaneous clearance of acute hepatitis C virus and jaundice.
        Gastroenterology. 2010; 139
        • Ragonnet R.
        • Deuffic-Burban S.
        • Boesecke C.
        • et al.
        Estimating the time to diagnosis and the chance of spontaneous clearance during acute hepatitis C in human immunodeficiency virus-infected individuals.
        Open Forum Infect Dis. 2017; 4 (ofw235)
        • Zeuzem S.
        • Dusheiko G.M.
        • Salupere R.
        • et al.
        Sofosbuvir and ribavirin in HCV genotypes 2 and 3.
        N Engl J Med. 2014; 370 (140504060027001): 1993-2001
        • Foster G.R.
        • Afdhal N.
        • Roberts S.K.
        • et al.
        Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection.
        N Engl J Med. 2015; 373: 2599-2607
        • Luetkemeyer A.F.
        • McDonald C.
        • Ramgopal M.
        • Noviello S.
        • Bhore R.
        • Ackerman P.
        12 weeks of daclatasvir in combination with sofosbuvir for HIV–HCV coinfection (ALLY-2 study): efficacy and safety by HIV combination antiretroviral regimens.
        Clin Infect Dis. 2016; 62: 1489-1496
        • Banerjee D.
        • Reddy K.R.
        Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy.
        Aliment Pharmacol Ther. 2016; : 1-23
        • Asselah T.
        • Bourgeois S.
        • Pianko S.
        • et al.
        Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1–6 and compensated cirrhosis or advanced fibrosis.
        Liver Int. 2017; ([Epub ahead of print])
        • Sulkowski M.S.
        • Naggie S.
        • Lalezari J.
        • et al.
        Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.
        JAMA. 2014; 312: 353-361
        • Franco S.
        • Casadellà M.
        • Noguera-Julian M.
        • et al.
        No detection of the NS5àB S282T mutation in treatment-na ve genotype 1 HCV/HIV-1 coinfected patients using deep sequencing.
        J Clin Virol. 2013; 58: 726-729
        • Christiansen M.T.
        • Hullegie S.J.
        • Schutten M.
        • et al.
        Use of whole genome sequencing in the Dutch Acute HCV in HIV study: focus on transmitted antiviral resistance.
        Clin Microbiol Infect. 2017; 23 (123.e1–123.e4)
        • Pawlotsky J.M.
        Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus.
        Hepatology. 2011; 53: 1742-1751
        • Sarrazin C.
        • Dvory-Sobol H.
        • Svarovskaia E.S.
        • et al.
        Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir.
        Gastroenterology. 2016; 151: 501-512.e1
        • Wyles D.
        • Mangia A.
        • Cheng W.
        • et al.
        Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir.
        Antivir Ther. 2017; ([Epub ahead of print])
        • Kourtis A.P.
        • Bulterys M.
        • Hu D.J.
        • Jamieson D.J.
        HIV-HBV coinfection?a global challenge.
        N Engl J Med. 2012; 366: 1749-1752
        • Yeh M.-L.
        • Huang C.-F.
        • Hsieh M.-H.
        • et al.
        Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals.
        J Gastroenterol Hepatol. 2017; 32: 1754-1762
        • Mücke V.T.
        • Mücke M.M.
        • Peiffer K.-H.
        • et al.
        No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort.
        Aliment Pharmacol Ther. 2017; 46: 432-439
        • Chen G.
        • Wang C.
        • Chen J.
        • et al.
        Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis.
        Hepatology. 2017; 66: 13-26
        • Jamma S.
        • Hussain G.
        • Lau D.T.Y.
        Current concepts of HBV/HCV coinfection: coexistence, but not necessarily in harmony.
        Curr Hepat Rep. 2010; 9: 260-269
        • Schüttler C.G.
        • Fiedler N.
        • Schmidt K.
        • Repp R.
        • Gerlich W.H.
        • Schaefer S.
        Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein.
        J Hepatol. 2002; 37: 855-862
        • Chen S.-Y.
        • Kao C.-F.
        • Chen C.-M.
        • et al.
        Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein.
        J Biol Chem. 2003; 278: 591-607
        • Götte M.
        • Feld J.J.
        Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.
        Nat Publ Gr. 2016; 13: 338-351
        • EASL
        EASL clinical practice guidelines: management of chronic hepatitis B virus infection.
        J Hepatol. 2012; 57: 167-185
        • Socías M.
        • Ti L.
        • Dong H.
        • et al.
        High prevalence of willingness to use direct-acting antiviral-based regimens for hepatitis C virus (HCV) infection among HIV/HCV coinfected people who use drugs.
        HIV Med. 2017; 18: 647-654